Sorry!! The article you are trying to read is not available now.
Bristol-Myers Rises After FDA Approves Blood Thinner Eliquis
MINYANVILLE ORIGINAL Shares of Bristol-Myers Squibb (NYSE:BMY) are rising after the drug maker won US approval for Eliquis its blood-thinning treatment aimed at preventing strokes and serious blood clots. Bristol-Myers and development partner Pfizer (NYSE:PFE) got word of the approval Friday afternoon almost three months earlier than a deadline set by the Food and Drug Administration. The FDA rejected the drug last June saying the companies needed to provide more information to show the medicine works and is safe. Eliquis is an alternative to warfarin which has been used for decades. Other companies including Johnson & Johnson (NYSE:JNJ) and ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here